Theratechnologies (TSE:TH) reached a new 52-week high during trading on Friday . The stock traded as high as C$11.45 and last traded at C$11.43, with a volume of 50513 shares changing hands. The stock had previously closed at C$11.26.
TH has been the topic of a number of research analyst reports. National Bank Financial increased their price target on Theratechnologies from C$8.75 to C$11.00 and gave the company an “outperform” rating in a research note on Wednesday, March 7th. Canaccord Genuity increased their price target on Theratechnologies from C$9.50 to C$13.00 in a research note on Wednesday, March 7th. Finally, CIBC increased their price target on Theratechnologies from C$10.30 to C$15.00 in a research note on Wednesday, March 7th.
Theratechnologies (TSE:TH) last posted its quarterly earnings results on Thursday, April 5th. The company reported C($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of C($0.05) by C$0.01. Theratechnologies had a negative return on equity of 38.09% and a negative net margin of 33.47%. The business had revenue of C$10.22 million for the quarter, compared to analysts’ expectations of C$11.20 million.
In other news, Director Jean-Denis Talon acquired 2,700 shares of the stock in a transaction on Monday, April 9th. The shares were purchased at an average price of C$9.44 per share, for a total transaction of C$25,488.00. In the last 90 days, insiders purchased 4,100 shares of company stock worth $37,792.
Theratechnologies Company Profile
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada.
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.